Perspectives on the impact of vortioxetine on the treatment armamentarium of major depressive disorder

References

• Bains N, Abdijadid S. Major depressive disorder. StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 [cited 2023 Nov 3]. Available from: http://www.ncbi.nlm.nih.gov/books/NBK559078/.
   Google Scholar
• Zajecka J, Kornstein SG, Blier P. Residual symptoms in major depressive disorder: prevalence, effects, and management: (academic highlights). J Clin Psychiatry. 2013;74(4):407–414. doi: 10.4088/JCP.12059ah1
   PubMed Web of Science ®Google Scholar
• Israel JA. The impact of residual symptoms in major depression. Pharmaceuticals. 2010;3(8):2426–2440. doi: 10.3390/ph3082426
   Google Scholar
• Alexander L, Young AH. Recent advances in the psychopharmacology of major depressive disorder. BJPsych Adv. 2023;29:117–130.
   Google Scholar
• Perez-Caballero L, Torres-Sanchez S, Romero-López-Alberca C, et al. Monoaminergic system and depression. Cell Tissue Res. 2019;377(1):107–113. doi: 10.1007/s00441-018-2978-8
   PubMed Web of Science ®Google Scholar
• Edinoff AN, Akuly HA, Hanna TA, et al. Selective serotonin reuptake inhibitors and adverse effects: a narrative review. Neurol Int. 2021;13(3):387–401. doi: 10.3390/neurolint13030038
   PubMed Web of Science ®Google Scholar
• Zhang X, Cai Y, Hu X, et al. Systematic review and meta-analysis of vortioxetine for the treatment of major depressive disorder in adults. Front Psychiatry. 2022;13:922648. doi: 10.3389/fpsyt.2022.922648
   PubMed Web of Science ®Google Scholar
• Papalexi E, Galanopoulos A, Kontis D, et al. Real-world effectiveness of vortioxetine in outpatients with major depressive disorder: functioning and dose effects. BMC Psychiatry. 2022;22(1):548. doi: 10.1186/s12888-022-04109-5
   PubMed Web of Science ®Google Scholar
• Food and drug administration. Trintellix (Vortioxetine) Prescribing Information. 2018. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/204447s026lbl.pdf
   Google Scholar
• European Medicines Agency. Brintellix: EPAR - Product Information; 2023.
   Google Scholar
• D’Agostino A, English CD, Rey JA. Vortioxetine (brintellix): a new serotonergic antidepressant. P T. 2015;40:36–40.
   PubMedGoogle Scholar
• Stenkrona P, Halldin C, Lundberg J. 5-HTT and 5-HT1A receptor occupancy of the novel substance vortioxetine (lu AA21004). A PET study in control subjects. Eur Neuropsychopharmacol. 2013;23(10):1190–1198. doi: 10.1016/j.euroneuro.2013.01.002
   PubMed Web of Science ®Google Scholar
• Houle S, Ginovart N, Hussey D, et al. Imaging the serotonin transporter with positron emission tomography: initial human studies with [11C]DAPP and [11C]DASB. Eur J Nucl Med. 2000;27(11):1719–1722. doi: 10.1007/s002590000365
   PubMedGoogle Scholar
• Sanchez C, Asin KE, Artigas F. Vortioxetine, a novel antidepressant with multimodal activity: review of preclinical and clinical data. Pharmacol Ther. 2015;145:43–57.
   PubMed Web of Science ®Google Scholar
• Popova NK, Naumenko VS. 5-HT1A receptor as a key player in the brain 5-HT system. Rev Neurosci. 2013:1–14. doi: 10.1515/revneuro-2012-0082
   PubMed Web of Science ®Google Scholar
• Westrich L, Haddjeri N, Dkhissi-Benyahya O, et al. Involvement of 5-HT7 receptors in vortioxetine’s modulation of circadian rhythms and episodic memory in rodents. Neuropharmacology. 2015;89:382–390. doi: 10.1016/j.neuropharm.2014.10.015
   PubMed Web of Science ®Google Scholar
• Bijata M, Bączyńska E, Müller FE, et al. Activation of the 5-HT7 receptor and MMP-9 signaling module in the hippocampal CA1 region is necessary for the development of depressive-like behavior. Cell Rep. 2022;38(11):110532. doi: 10.1016/j.celrep.2022.110532
   PubMed Web of Science ®Google Scholar
• Naumenko VS, Popova NK, Lacivita E, et al. Interplay between serotonin 5‐ HT 1A and 5‐ HT 7 receptors in depressive disorders. CNS Neurosci Ther. 2014;20:582–590. doi: 10.1111/cns.12247
   PubMed Web of Science ®Google Scholar
• Diego-Adeliño JD, Crespo JM, Mora F, et al. Vortioxetine in major depressive disorder: from mechanisms of action to clinical studies. An updated review. Expert Opin Drug Saf. 2022;21(5):673–690. doi: 10.1080/14740338.2022.2019705
   PubMed Web of Science ®Google Scholar
• Stahl SM. Modes and nodes explain the mechanism of action of vortioxetine, a multimodal agent (MMA): modifying serotonin’s downstream effects on glutamate and GABA (gamma amino butyric acid) release. CNS Spectr. 2015;20(4):331–336. doi: 10.1017/S1092852915000334
   PubMed Web of Science ®Google Scholar
• Schweimer JV, Brouard JT, Li Y, et al. In vivo electrophysiological study of the targeting of 5‐HT 3 receptor‐expressing cortical interneurons by the multimodal antidepressant, vortioxetine. Eur J Neurosci. 2022;55(6):1409–1423. doi: 10.1111/ejn.15623
   PubMed Web of Science ®Google Scholar
• Bennabi D, Haffen E, Van Waes V. Vortioxetine for cognitive enhancement in major depression: from animal models to clinical research. Front Psychiatry. 2019;10:771.
   PubMed Web of Science ®Google Scholar
• Okubo R, Hasegawa T, Fukuyama K, et al. Current limitations and candidate potential of 5-HT7 receptor antagonism in psychiatric pharmacotherapy. Front Psychiatry. 2021;12:623684. doi: 10.3389/fpsyt.2021.623684
   PubMed Web of Science ®Google Scholar
• Chen G, Højer A-M, Areberg J, et al. Vortioxetine: clinical pharmacokinetics and drug interactions. Clin Pharmacokinet. 2018;57(6):673–686. doi: 10.1007/s40262-017-0612-7
   PubMed Web of Science ®Google Scholar
• Wang Y, Nomikos GG, Karim A, et al. Effect of vortioxetine on cardiac repolarization in healthy adult male subjects: results of a thorough QT/QTc study. Clinical Pharm In Drug Dev. 2013;2(4):298–309. doi: 10.1002/cpdd.51
   PubMed Web of Science ®Google Scholar
• Baldwin DS, Chrones L, Florea I, et al. The safety and tolerability of vortioxetine: analysis of data from randomized placebo-controlled trials and open-label extension studies. J Psychopharmacol. 2016;30(3):242–252. doi: 10.1177/0269881116628440
   PubMed Web of Science ®Google Scholar
• Citrome L. Vortioxetine for major depressive disorder: an indirect comparison with duloxetine, escitalopram, levomilnacipran, sertraline, venlafaxine, and vilazodone, using number needed to treat, number needed to harm, and likelihood to be helped or harmed. J Affective Disorders. 2016;196:225–233.
   PubMed Web of Science ®Google Scholar
• Siwek M, Gorostowicz A, Bosak M, et al. Case report: vortioxetine in the treatment of depressive symptoms in patients with epilepsy—case series. Front Pharmacol. 2022;13:852042. doi: 10.3389/fphar.2022.852042
   PubMed Web of Science ®Google Scholar
• Taskiran M, Unal G. Vortioxetine suppresses epileptiform activity and cognition deficits in a chronic PTZ‐induced kindling rat model. Epileptic Disord. 2021;23(6):893–900. doi: 10.1684/epd.2021.1344
   PubMed Web of Science ®Google Scholar
• Baldwin DS, Necking O, Schmidt SN, et al. Efficacy and safety of vortioxetine in treatment of patients with major depressive disorder and common co-morbid physical illness. J Affective Disorders. 2022;311:588–594. doi: 10.1016/j.jad.2022.05.098
   PubMed Web of Science ®Google Scholar
• Siwek M, Chrobak AA, Gorostowicz A, et al. Withdrawal symptoms following discontinuation of vortioxetine—retrospective chart review. Pharmaceuticals. 2021;14(5):451. doi: 10.3390/ph14050451
   Web of Science ®Google Scholar
• Li Z, Liu S, Wu Q, et al. Effectiveness and safety of vortioxetine for the treatment of major depressive disorder in the real world: a systematic review and meta-analysis. Int J Neuropsychopharmacol. 2023;26(6):373–384. doi: 10.1093/ijnp/pyad018
   PubMed Web of Science ®Google Scholar
• Thase ME, Mahableshwarkar AR, Dragheim M, et al. A meta-analysis of randomized, placebo-controlled trials of vortioxetine for the treatment of major depressive disorder in adults. Eur Neuropsychopharmacol. 2016;26(6):979–993. doi: 10.1016/j.euroneuro.2016.03.007
   PubMed Web of Science ®Google Scholar
• Jain R, Mahableshwarkar AR, Jacobsen PL, et al. A randomized, double-blind, placebo-controlled 6-wk trial of the efficacy and tolerability of 5 mg vortioxetine in adults with major depressive disorder*. Int J Neuropsychopharmacol. 2013;16(2):313–321. doi: 10.1017/S1461145712000727
   PubMed Web of Science ®Google Scholar
• Katona C, Hansen T, Olsen CK. A randomized, double-blind, placebo-controlled, duloxetine-referenced, fixed-dose study comparing the efficacy and safety of Lu AA21004 in elderly patients with major depressive disorder. Int Clin Psychopharmacol. 2012;27(4):215–223. doi: 10.1097/YIC.0b013e3283542457
   PubMed Web of Science ®Google Scholar
• Nomikos GG, Tomori D, Zhong W, et al. Efficacy, safety, and tolerability of vortioxetine for the treatment of major depressive disorder in patients aged 55 years or older. CNS Spectr. 2017;22(4):348–362. doi: 10.1017/S1092852916000626
   PubMed Web of Science ®Google Scholar
• Christensen MC, Schmidt SN, Grande I. Effectiveness of vortioxetine in patients with major depressive disorder and early-stage dementia: the MEMORY study. J Affective Disorders. 2023;338:423–431.
   PubMed Web of Science ®Google Scholar
• Santos García D, Alonso Losada MG, Cimas Hernando I, et al. Vortioxetine improves depressive symptoms and cognition in Parkinson’s disease patients with major depression: an open-label prospective study. Brain Sci. 2022;12(11):1466. doi: 10.3390/brainsci12111466
   PubMed Web of Science ®Google Scholar
• Mattingly GW, Ren H, Christensen MC, et al. Effectiveness of vortioxetine in patients with major depressive disorder in real-world clinical practice: results of the Relieve study. Front Psychiatry. 2022;13:824831. doi: 10.3389/fpsyt.2022.824831
   PubMed Web of Science ®Google Scholar
• Christensen MC, McIntyre RS, Adair M, et al. Clinical benefits of vortioxetine 20 mg/day in patients with major depressive disorder. CNS Spectr. 2023:1–9. doi: 10.1017/S1092852923002249
   Web of Science ®Google Scholar
• Boulenger J-P, Loft H, Florea I. A randomized clinical study of lu AA21004 in the prevention of relapse in patients with major depressive disorder. J Psychopharmacol. 2012;26(11):1408–1416. doi: 10.1177/0269881112441866
   PubMed Web of Science ®Google Scholar
• Thase ME, Jacobsen PL, Hanson E, et al. Vortioxetine 5, 10, and 20 mg significantly reduces the risk of relapse compared with placebo in patients with remitted major depressive disorder: the RESET study. J Affective Disorders. 2022;303:123–130. doi: 10.1016/j.jad.2022.02.002
   PubMed Web of Science ®Google Scholar
• Jacobsen PL, Mahableshwarkar AR, Palo WA, et al. Treatment-emergent sexual dysfunction in randomized trials of vortioxetine for major depressive disorder or generalized anxiety disorder: a pooled analysis. CNS Spectr. 2016;21(5):367–378. doi: 10.1017/S1092852915000553
   PubMed Web of Science ®Google Scholar
• Jacobsen PL, Mahableshwarkar AR, Chen Y, et al. Effect of vortioxetine vs. Escitalopram on sexual functioning in adults with well-treated major depressive disorder experiencing SSRI-Induced sexual dysfunction. J Sex Med. 2015;12(10):2036–2048. doi: 10.1111/jsm.12980
   PubMed Web of Science ®Google Scholar
• Cao B, Park C, Subramaniapillai M, et al. The efficacy of vortioxetine on anhedonia in patients with major depressive disorder. Front Psychiatry. 2019;10:17. doi: 10.3389/fpsyt.2019.00017
   PubMed Web of Science ®Google Scholar
• McIntyre RS, Loft H, Christensen MC. Efficacy of vortioxetine on anhedonia: results from a pooled analysis of short-term studies in patients with major depressive disorder. NDT. 2021;17:575–585. doi: 10.2147/NDT.S296451
   Google Scholar
• de Carlo V, Vismara M, Grancini B, et al. Effectiveness, tolerability, and dropout rates of vortioxetine in comorbid depression: a naturalistic study. Hum Psychopharmacol. 2020;35(5):e2750. doi: 10.1002/hup.2750
   PubMed Web of Science ®Google Scholar
• Siwek M, Chrobak A, Sołtys Z, et al. A naturalistic, 24-week, open-label, add-on study of vortioxetine in bipolar depression. Psychiatr Pol. 2022;56(3):509–522. doi: 10.12740/PP/OnlineFirst/132962
   PubMed Web of Science ®Google Scholar
• Goodwin GM, Price J, De Bodinat C, et al. Emotional blunting with antidepressant treatments: a survey among depressed patients. J Affect Disord. 2017;221:31–35. doi: 10.1016/j.jad.2017.05.048
   PubMed Web of Science ®Google Scholar
• Price J, Cole V, Goodwin GM. Emotional side-effects of selective serotonin reuptake inhibitors: qualitative study. Br J Psychiatry. 2009;195(3):211–217. doi: 10.1192/bjp.bp.108.051110
   PubMed Web of Science ®Google Scholar
• Ma H, Cai M, Wang H. Emotional blunting in patients with major depressive disorder: a brief non-systematic review of Current research. Front Psychiatry. 2021;12:792960. doi: 10.3389/fpsyt.2021.792960
   PubMed Web of Science ®Google Scholar
• De Fruyt J, Sabbe B, Demyttenaere K. Anhedonia in depressive disorder: a narrative review. Psychopathology. 2020;53(5–6):274–281. doi: 10.1159/000508773
   PubMed Web of Science ®Google Scholar
• Fagiolini A, Florea I, Loft H, et al. Effectiveness of vortioxetine on emotional blunting in patients with major depressive disorder with inadequate response to SSRI/SNRI treatment. J Affective Disorders. 2021;283:472–479. doi: 10.1016/j.jad.2020.11.106
   PubMed Web of Science ®Google Scholar
• Pan Z, Park C, Brietzke E, et al. Cognitive impairment in major depressive disorder. CNS Spectr. 2019;24(1):22–29. doi: 10.1017/S1092852918001207
   PubMed Web of Science ®Google Scholar
• Perini G, Cotta Ramusino M, Sinforiani E, et al. Cognitive impairment in depression: recent advances and novel treatments. NDT. 2019;15:1249–1258. doi: 10.2147/NDT.S199746
   Google Scholar
• McIntyre RS, Florea I, Tonnoir B, et al. Efficacy of vortioxetine on cognitive functioning in working patients with major depressive disorder. J Clin Psychiatry. 2017;78(1):115–121. doi: 10.4088/JCP.16m10744
   PubMed Web of Science ®Google Scholar
• Harrison JE, Lophaven S, Olsen CK. Which cognitive domains are improved by treatment with Vortioxetine? IJNPPY. 2016;19(10):yw054. doi: 10.1093/ijnp/pyw054
   Google Scholar
• Huang I-C, Chang T-S, Chen C, et al. Effect of vortioxetine on cognitive impairment in patients with major depressive disorder: a systematic review and meta-analysis of randomized controlled trials. Int J Neuropsychopharmacol. 2022;25(12):969–978. doi: 10.1093/ijnp/pyac054
   PubMed Web of Science ®Google Scholar
• McIntyre R, Harrison J, Loft H, et al. The effects of vortioxetine on cognitive function in patients with major depressive disorder: a meta-analysis of three randomized controlled trials. IJNPPY. 2016;19(10):yw055. doi: 10.1093/ijnp/pyw055
   Google Scholar
• Chokka P, Bougie J, Rampakakis E, et al. Assessment in work productivity and the relationship with cognitive symptoms (AtWorc): primary analysis from a Canadian open-label study of vortioxetine in patients with major depressive disorder (MDD). CNS Spectr. 2019;24(3):338–347. doi: 10.1017/S1092852918000913
   PubMed Web of Science ®Google Scholar
• Tiller JWG. Depression and anxiety. Med j Aust [Internet]. 2013 [cited 2023 Nov 3];199(S6). doi: 10.5694/mja12.10628
   Google Scholar
• Christensen MC, Schmidt S, Grande I. Effectiveness of vortioxetine in patients with major depressive disorder comorbid with generalized anxiety disorder: results of the Reconnect study. J Psychopharmacol. 2022;36:566–577.
   PubMed Web of Science ®Google Scholar
• Olivier B, van Wijngaarden I, Soudijn W. 5-HT3 receptor antagonists and anxiety; a preclinical and clinical review. Eur Neuropsychopharmacol. 2000;10(2):77–95. doi: 10.1016/S0924-977X(99)00065-6
   PubMed Web of Science ®Google Scholar
• Montgomery SA, Nielsen RZ, Poulsen LH, et al. A randomised, double-blind study in adults with major depressive disorder with an inadequate response to a single course of selective serotonin reuptake inhibitor or serotonin-noradrenaline reuptake inhibitor treatment switched to vortioxetine or agomelatine. Hum Psychopharmacol. 2014;29(5):470–482. doi: 10.1002/hup.2424
   PubMed Web of Science ®Google Scholar
• Baldwin DS, Florea I, Jacobsen PL, et al. A meta-analysis of the efficacy of vortioxetine in patients with major depressive disorder (MDD) and high levels of anxiety symptoms. J Affective Disorders. 2016;206:140–150. doi: 10.1016/j.jad.2016.07.015
   PubMed Web of Science ®Google Scholar
• Almeida SS, Christensen MC, Simonsen K, et al. Effectiveness of vortioxetine in patients with major depressive disorder and co-morbid generalized anxiety disorder in routine clinical practice: a subgroup analysis of the Relieve study. J Psychopharmacol. 2023;37(3):279–288. doi: 10.1177/02698811221132468
   PubMed Web of Science ®Google Scholar
• Renaud-Charest O, Lui LMW, Eskander S, et al. Onset and frequency of depression in post-COVID-19 syndrome: a systematic review. J Psychiatr Res. 2021;144:129–137. doi: 10.1016/j.jpsychires.2021.09.054
   PubMed Web of Science ®Google Scholar
• di Nicola M, Pepe M, Montanari S, et al. Vortioxetine improves physical and cognitive symptoms in patients with post-COVID-19 major depressive episodes. Eur Neuropsychopharmacol. 2023;70:21–28. doi: 10.1016/j.euroneuro.2023.02.006
   PubMed Web of Science ®Google Scholar
• McIntyre RS, Phan L, Kwan ATH, et al. Vortioxetine for the treatment of post-COVID-19 condition: a randomized controlled trial. Brain. 2023;147(3):849–857. doi: 10.1093/brain/awad377
   Google Scholar